Motion to Dismiss Denied in Amgen v. Hospira BPCIA

Goodwin
Contact

Goodwin

At the end of last month, Judge Connolly denied defendants Hospira and Pfizer’s motion to dismiss following a telephone conference with the parties.  We previously reported back in February 2020 that Amgen sued Pfizer and its affiliate Hospira for patent infringement of U.S. Patent No. 8,273,707 (“’707 patent”) based on their proposed biosimilar of NEULASTA (pegfilgrastim). The ’707 patent claims processes for purifying proteins that require, among other limitations, using two specified salts “wherein the concentration of each of the first salt and the second salt in the mixture is between about 0.1 M and about 1.0 [M].”

On March 4, 2020, defendants filed a motion to dismiss for failure to state a claim, asserting that Pfizer’s process does not meet the concentration limitation as a matter of law, and further arguing that this was the “second time Amgen has sued a biosimilar manufacturer in this Court alleging infringement of [U.S. Patent No. 8,273,707].” They asserted that “[t]he first lawsuit, against Coherus, ended with a dismissal under Rule 12(b)(6) [for failure to state a claim], affirmed by the Federal Circuit, based on Amgen’s concessions made during patent prosecution.” Defendants argued that the present case should be dismissed for similar reasons. Plaintiffs responded in their Answering Brief that Amgen “did not distinguish its invention from the prior art based on a particular concentration of salt, but rather on which and how many salts were employed and Amgen’s statements in the prosecution of the parent are not a disclaimer as to the salt concentrations claimed in the patent.” Defendants responded in their reply briefing that their motion to dismiss turned on a single legal issue, namely “whether Amgen clearly and unmistakably surrendered salt concentrations below 0.040 M during prosecution.”

We will continue to monitor developments in this case.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.